Compare Alcon AG (ALC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Illumina, Inc. — how do they compare? Alcon AG trades at $72.57 (market cap $36.44B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Alcon AG is the larger of the two by market cap, and Alcon AG pays a 0.48% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ALC | ILMN | |
|---|---|---|
Market Cap | $36.44B | $29.12B |
Sector | Health | Health |
52-Week High | $90.12 | $205.10 |
52-Week Low | $62.02 | $91.00 |
Enterprise Value | $40.28B | $30.48B |
Dividend Yield | 0.48% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
